Can-Fite Biopharma LTD. (CANF) — SEC Filings

Overview

Can-Fite Biopharma LTD. (CANF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 6, 2026: Can-Fite BioPharma Ltd. filed an EFFECT form on April 6, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999999995-26-001089, relates to Act 33 and File No. 333-294760. The effectiveness date is noted as April 3, 2026.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bullish, 1 bearish, 41 neutral. The dominant filing sentiment for Can-Fite Biopharma LTD. is neutral.

Filing Type Overview

Can-Fite Biopharma LTD. (CANF) has filed 46 6-K, 1 EFFECT, 2 20-F, 1 SC 13G/A with the SEC between Jul 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Apr 23, 2026
• Can-Fite BioPharma Registration Statement Declared Effective — EFFECT · Apr 6, 2026 Risk: low
  Can-Fite BioPharma Ltd. filed an EFFECT form on April 6, 2026, indicating the effectiveness of a registration statement. The filing, with SEC Accession No. 9999
• Can-Fite BioPharma Files 6-K Report — 6-K · Mar 30, 2026 Risk: low
  Can-Fite BioPharma Ltd. filed a Form 6-K on March 30, 2026, reporting information as a foreign issuer. The filing includes a press release dated March 30, 2026,
• Can-Fite's Losses Mount to $9.8M in 2025 Amid Reverse Split — 20-F · Mar 26, 2026 Risk: high
  Can-Fite BioPharma Ltd. (CANF) reported a net loss of approximately $9.8 million in 2025, an increase from $7.9 million in 2024 and $7.6 million in 2023, bringi
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Dec 29, 2025 Risk: low
  Can-Fite BioPharma Ltd. filed a Form 6-K on December 29, 2025, to report a press release issued on December 26, 2025. This filing incorporates the press release
• 6-K Filing — 6-K · Dec 23, 2025
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Dec 16, 2025 Risk: low
  On December 16, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is relevant to several of their existing
• 6-K Filing — 6-K · Nov 21, 2025
• Can-Fite BioPharma Files 6-K Report — 6-K · Nov 20, 2025 Risk: low
  On November 20, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8
• 6-K Filing — 6-K · Nov 18, 2025
• 6-K Filing — 6-K · Nov 10, 2025
• 6-K Filing — 6-K · Nov 3, 2025
• Can-Fite BioPharma to Restructure into New Entity '03 Life Sciences' — 6-K · Oct 3, 2025 Risk: medium
  On October 3, 2025, Can-Fite BioPharma Ltd. announced its intention to incorporate its existing business into a new entity, '03 Life Sciences'. This strategic m
• Can-Fite BioPharma Files 6-K, Updates SEC Filings — 6-K · Sep 15, 2025 Risk: low
  On September 15, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is intended to update its Registration
• Can-Fite BioPharma Ltd. Files 6-K for June 30, 2025 — 6-K · Aug 28, 2025 Risk: low
  Can-Fite BioPharma Ltd. filed a Form 6-K on August 28, 2025, reporting its financial results for the period ending June 30, 2025. The filing includes financial
• Can-Fite BioPharma Pancreatic Cancer Study Hits Enrollment Milestone — 6-K · Jul 30, 2025 Risk: medium
  On July 30, 2025, Can-Fite BioPharma Ltd. announced that its Phase 2a study for pancreatic cancer, utilizing its drug Namodenoson, has achieved over a 50% enrol
• Can-Fite BioPharma's Piclidenoson Shows Promise in HS Study — 6-K · Jul 29, 2025 Risk: medium
  On July 28, 2025, Can-Fite BioPharma Ltd. announced that its investigational drug, Piclidenoson, showed positive results in a Phase II study for hidradenitis su
• Can-Fite's Piclidenoson Shows Promise for Vascular Dementia — 6-K · Jul 28, 2025 Risk: medium
  On July 28, 2025, Can-Fite BioPharma Ltd. announced a breakthrough study from UCLA demonstrating that its drug, Piclidenoson, shows promise as a treatment for v
• Can-Fite BioPharma Shareholders Approve All Six Proposals — 6-K · Jun 30, 2025 Risk: low
  On June 30, 2025, Can-Fite BioPharma Ltd. held its Annual General Meeting of Shareholders where all six proposals presented were approved. These proposals were
• Can-Fite BioPharma Annual Meeting Adjourned Due to Lack of Quorum — 6-K · Jun 23, 2025 Risk: medium
  Can-Fite BioPharma Ltd. announced on June 23, 2025, that its Annual General Meeting of Shareholders was adjourned for one week due to a lack of quorum. The meet
• Can-Fite BioPharma to Present Pancreatic Cancer Study Update at BIO Convention — 6-K · Jun 16, 2025 Risk: medium
  On June 16, 2025, Can-Fite BioPharma Ltd. announced it will present progress on its Phase IIa pancreatic cancer study at the 2025 BIO International Convention i
• Can-Fite BioPharma Files Form 6-K — 6-K · May 16, 2025 Risk: low
  On May 16, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating this report into its existing Registration Statements on Form S-8 and Form F-3. The fil
• Can-Fite BioPharma Raises $175M for Liver Cancer & Psoriasis Drugs — 6-K · May 5, 2025 Risk: medium
  On May 5, 2025, Can-Fite BioPharma Ltd. announced it has raised a total of $175 million to date for the development of its drugs Namodenoson and Piclidenoson. T
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Apr 17, 2025 Risk: low
  On April 17, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, reporting information for the month of April 2025. This filing incorporates by reference a press re
• Can-Fite BioPharma Files 6-K, Incorporates Previous Filings — 6-K · Apr 15, 2025 Risk: low
  On April 14, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K report. This filing incorporates by reference previous registration statements on Form S-8 and Form
• Can-Fite BioPharma Files 2024 Annual Report — 20-F · Apr 14, 2025 Risk: medium
  Can-Fite BioPharma Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is involved in th
• Can-Fite BioPharma Establishes New Subsidiary for Drug Development — 6-K · Mar 24, 2025 Risk: medium
  On March 24, 2025, Can-Fite BioPharma Ltd. announced the incorporation of its wholly-owned subsidiary, CFB Therapeutics Ltd., in Israel. This subsidiary will fo
• Can-Fite BioPharma Files 6-K Report — 6-K · Mar 20, 2025 Risk: low
  On March 20, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating a press release by reference into its existing SEC registration statements. This fili
• Can-Fite BioPharma Ltd. Incorporates Israeli Subsidiary — 6-K · Mar 19, 2025 Risk: low
  On March 19, 2025, Can-Fite BioPharma Ltd. announced the incorporation of its wholly-owned subsidiary, CF Pharma Ltd., in Israel. This move is intended to facil
• Can-Fite BioPharma Files Routine 6-K Report — 6-K · Mar 18, 2025 Risk: low
  On March 18, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 an
• Can-Fite BioPharma Publishes Namodenoson Liver Cancer Research — 6-K · Mar 3, 2025 Risk: medium
  On March 3, 2025, Can-Fite BioPharma Ltd. announced a press release highlighting the publication of research on Namodenoson for liver cancer treatment. The publ
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Feb 18, 2025 Risk: low
  On February 18, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is related to its existing Registration
• Can-Fite BioPharma to Present Namodenoson Obesity Data — 6-K · Feb 5, 2025 Risk: medium
  On February 5, 2025, Can-Fite BioPharma Ltd. announced its participation in the BIO CEO & Investor Conference 2025. The company will present data on the anti-ob
• Can-Fite BioPharma Secures US Patent for Obesity Drug Namodenoson — 6-K · Jan 27, 2025 Risk: medium
  On January 27, 2025, Can-Fite BioPharma Ltd. announced that the US Patent Office granted them a patent for Namodenoson, specifically for its use as an anti-obes
• ASCO Recognizes Can-Fite's Namodenoson Liver Protection — 6-K · Dec 30, 2024 Risk: medium
  On December 30, 2024, Can-Fite BioPharma Ltd. announced that the American Society of Clinical Oncology (ASCO) recognized the liver-protective effects of their a
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Dec 4, 2024 Risk: low
  Can-Fite BioPharma Ltd. filed a Form 6-K on December 4, 2024, to report information for the month of December 2024. The filing incorporates by reference a press
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Nov 12, 2024 Risk: low
  On November 11, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is related to their ongoing registration
• Can-Fite BioPharma's Namodenoson Drug Gets Australian Patent Allowance — 6-K · Nov 4, 2024 Risk: low
  Can-Fite BioPharma Ltd. announced on November 4, 2024, that its anti-obesity drug, Namodenoson, has received a patent allowance in Australia. This development i
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Oct 18, 2024 Risk: low
  On October 18, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference the first and third paragraphs of a press release (Exhibit 99.1) into
• Can-Fite BioPharma Ltd. Files 6-K, Incorporates Press Release — 6-K · Oct 9, 2024 Risk: low
  On October 9, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 a
• Can-Fite BioPharma Licenses Piclidenoson, Projects $325M Income — 6-K · Sep 24, 2024 Risk: medium
  On September 24, 2024, Can-Fite BioPharma Ltd. announced that Vetbiolix exercised its option to license Piclidenoson for veterinary osteoarthritis. This agreeme
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Sep 16, 2024 Risk: low
  On September 16, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K. This report incorporates by reference certain paragraphs from a press release into their existi
• Can-Fite BioPharma Files Form 6-K — 6-K · Aug 30, 2024 Risk: low
  On August 30, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating this report into its existing registration statements on Form S-8 and Form F-3. The
• Can-Fite BioPharma Ltd. Files 6-K for June 30, 2024 — 6-K · Aug 29, 2024 Risk: low
  Can-Fite BioPharma Ltd. filed a Form 6-K on August 29, 2024, reporting its financial results for the period ending June 30, 2024. The filing includes financial
• Can-Fite BioPharma Files 6-K, Incorporates Inducement Letter — 6-K · Aug 12, 2024 Risk: medium
  On August 8, 2024, Can-Fite BioPharma Ltd. entered into an inducement letter with an investor. This letter is incorporated by reference into several of the Comp
• Can-Fite BioPharma Raises $10.5M in Public Offering — 6-K · Aug 9, 2024 Risk: medium
  On August 8, 2024, Can-Fite BioPharma Ltd. announced the closing of its previously disclosed underwritten public offering, raising gross proceeds of approximate
• Can-Fite BioPharma Updates Namodenoson Patent Status — 6-K · Jul 29, 2024 Risk: medium
  On July 29, 2024, Can-Fite BioPharma Ltd. issued a press release providing an update on its Namodenoson patent. The company is seeking to extend the patent prot
• Can-Fite BioPharma Files 6-K, Incorporates Press Release — 6-K · Jul 11, 2024 Risk: low
  Can-Fite BioPharma Ltd. filed a Form 6-K on July 11, 2024, to incorporate by reference a press release into its existing Registration Statements on Form S-8 and
• Can-Fite BioPharma Holds Annual Shareholder Meeting — 6-K · Jul 3, 2024 Risk: low
  On July 3, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K to incorporate by reference into its existing registration statements. This filing relates to the comp

Risk Profile

Risk Assessment: Of CANF's 43 recent filings, 1 were flagged as high-risk, 17 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Motti Farbstein

Industry Context

Can-Fite BioPharma operates in the highly competitive biopharmaceutical sector, focusing on orally bioavailable small molecules targeting the A3 adenosine receptor. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory hurdles. Key therapeutic areas include cancer, liver, and inflammatory diseases, where numerous established players and emerging biotech firms are actively developing novel treatments.

Top Tags

registration-statement (13) · sec-filing (12) · drug-development (9) · 6-k (8) · filing (7) · foreign-private-issuer (6) · press-release (5) · biotech (5) · filing-update (3) · compliance (3)

Key Numbers

• Effectiveness Date: 2026-04-03 — The date the registration statement became effective.
• Filing Date: 2026-04-06 — The date the filing was accepted by the SEC.
• Net Loss: $9.8M — incurred in 2025, an increase from $7.9M in 2024
• Accumulated Deficit: $176.2M — as of December 31, 2025
• Reverse Stock Split Ratio: 1-for-3,000 — effected on ordinary shares on January 2, 2026
• Reverse ADS Split Ratio: 1-for-20 — effected on ADSs on January 5, 2026
• Ordinary Shares Outstanding: 2,618,425 — as of December 31, 2025
• Exchange Rate: NIS 3.19 — per $1.00 on December 31, 2025
• Piclidenoson Trial Stage: Phase III — Indicates significant progress in drug development for psoriasis.
• Reporting Period End: June 30, 2025 — Financial results are reported as of this date.
• Enrollment Milestone: 50% — Indicates significant progress in the Phase 2a study for pancreatic cancer.
• Proposals Approved: 6 — All proposals presented at the Annual General Meeting were approved by shareholders.
• Adjournment Period: 1 week — The meeting was postponed for one week.
• Total Funding Raised: $175M — Funds development of Namodenoson and Piclidenoson into Phase 3 trials.
• Fiscal Year End: 2024 — The period covered by the annual report.

Related Companies

CFBI

Frequently Asked Questions